Atlas Trials

Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer

Clinical trial NCT04156087 · COMPLETED

Trial details

NCT number
NCT04156087
Sponsor
Baki Topal
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreatic Cancer Non-resectable
Start date
2020-05-09
Primary completion
2024-01-29
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.